Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest lung cancer Stories

2014-04-19 23:00:42

ReportsnReports.com adds the latest report on “Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014” to its store. Order a copy of this report at http://www.reportsnreports.com/purchase.aspx?name=279869. Dallas, TX (PRWEB) April 19, 2014 This report provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial...

2014-04-17 23:01:36

Zoll, Kranz & Borgess, LLC, (ZKB) a pharmaceutical and medical device litigation firm, is currently investigating claims of men who developed melanoma after taking the pharmaceutical drug, Viagra (sildenafil citrate), which is marketed by the US-based pharmaceutical company, Pfizer. Toledo, OH (PRWEB) April 17, 2014 Studies have suggested that sildenafil use may increase the invasiveness of melanoma cells, which may raise the possible adverse effect of melanoma. On April 7, 2014, a...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...

2014-04-11 23:03:52

Lifeinsurancequoteterm.net (http://lifeinsurancequoteterm.net/) announces a new blog post, “How to find the most affordable term life insurance if you suffer from lung cancer?” (PRWEB) April 11, 2014 Lifeinsurancequoteterm.net has released a new blog post explaining how to find affordable term life insurance rates for clients who have lung cancer. Clients who have been diagnosed with lung cancer can qualify for life coverage by applying for no medical exam life insurance. These plans...

2014-04-10 12:10:29

Preventing lung cancers from metastasizing to other parts of the body could provide benefit for patients against the leading cause of cancer death Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen). The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the...

2014-04-09 12:31:42

Initiating Phase Ib studies in NSCLC and AML in 2014 BERGEN, Norway, April 9, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that results from its successful Phase Ia clinical study for lead compound, BGB324, was presented at the American Association of Cancer Research annual conference, which took place on April 5-9, 2014. BGB324 is a first-in-class, highly selective small molecule inhibitor...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-04-09 10:43:30

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for...

2014-04-08 08:29:10

Celebrating Monica's Contributions in Memoriam WASHINGTON, April 8, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation announces Monica Barlow, formerly director of public relations for the Baltimore Orioles, as the April LUNGevity Hero for her contributions to the fight against lung cancer. An advocate for lung cancer research through her work with LUNGevity for more than four years, Monica was a vital voice for the lung cancer community. Her death in February saddened the lung cancer...

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »